Heli Harvala
MD, PhD, EUPHEM Alumni, FRCPath
Virology heli.harvala@utu.fi |
Virology; Clinical Virology; Public Health Virology; Transfusion Virology
Heli Harvala was appointed as a Professor of Virology at the Institute of Biomedicine, University of Turku, Finland in September, 2024.
She graduated in Medicine, obtained a MSc in Organic Chemistry and a PhD in Virology at the University of Turku, Finland, in 2003. Subsequently she completed her Medical Virology training in Edinburgh and became a Fellow of the Royal College of Pathologists in 2015. During that time, she joined the European Public Health Microbiology fellowship programme at the Public Health Agency of Sweden for two years before returning back to the UK. Over the last ten years, she has combined her work as a Consultant Medical Virologist with clinical, transfusion and public health related virology research.
She is a co-founder of the European Non-Polio Enterovirus Network (ENPEN) which evaluates the importance of enterovirus infections and monitors for their emergence together with collaborators from over 30 European countries. During COVID-19 pandemic, she was involved with setting up SARS-CoV-2 testing of convalescent plasma donors in England, and the related international REMAP-CAP trial. She also has wide interests in molecular epidemiology and next generation sequencing, and is involved with investigations into how next generation sequencing could be used to enhance the effectiveness of microbiological donation screening.
She leads the Blood Safety research team within the NIHR funded Blood and Transplant Research Unit at the University of Oxford. This research focuses on transfusion transmitted viral infections aiming to improve our understanding of current risks and preparedness for emerging pathogens. She also recently led the work in identifying occult hepatitis B infections as a blood transfusion risk in England and has done pioneering work to investigate pre-exposure prophylaxis use among syphilis infected blood donors. While these activieis continue, she is currently establishing her research group at the University of Turku.
Prof Harvala is widely published in the field of medical, transfusion and public health virology (over 130 peer reviewed publications, h-index 48). She is an executive committee member of European Society for Clinical Virology and the programme committee member for the European Society for Clinical Microbiology and infectious Diseases. She was recently appointed to the WHO European Region Commission for the Certification of Poliomyelitis Eradication, and previously chaired the WHO R&D Blueprint group on Picornaviruses, the Microbiology Specialist Interest Group for the British Blood Transfusion Society, the Panel of Senior Virology Examiners for the RCPath and the Standing Advisory Committee for Transfusion Transmitted Infections.
She is currently involved in the undergraduate teaching of medical and biomedical students, being responsible for the virology part of that. She has previously been involved in the Undergraduate teaching at the University College of London, University of Edinburgh, the University of Oulu and at the University of Turku. She is also actively engaging with Postgraduate teaching by supervising both PhD and MSc students, and has undertaken PhD Supervisors training at the University of Oxford. Furthermore, she has extensive experience in Clinical Virology specialty training; she has been trained educational supervisor in Clinical Virology since 2016 and trained Royal College of Pathologist Examiner in Clinical Virology since 2017.
Her interest includes developing training further and as an example, she developed a new three-day module in Phylogenetics and Bioinformatics for European Centre for Disease Control (ECDC) Stockholm with the microbiological cases studies in 2016. Subsequently, she led the developing and delivering this for the ECDC summer schools in Stockholm, 2016 and 2017, and for the ECDC EPIET/EUPHEM fellows in Berlin, 2017 and 2018.
- Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary (2021)
- Vox Sanguinis
- Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety? (2021)
- Transfusion
- Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020. (2021)
- Journal of Global Health
- Molecular epidemiology and evolutionary trajectory of emerging echovirus 30, Europe (2021)
- Emerging Infectious Diseases
- Recommendations for the introduction of metagenomic high-throughput sequencing in clinical virology, part I: Wet lab procedure (2021)
- Journal of Clinical Virology
- Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021 (2021)
- Eurosurveillance
- SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data (2021)
- Eurosurveillance
- Seroprevalence and Virologic Surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006-2017. (2021)
- Emerging Infectious Diseases
- Understanding the outcomes of COVID-19 - does the current model of an acute respiratory infection really fit? (2021)
- Journal of General Virology
- Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B1.1.7 Infection (2021)
- Journal of Infectious Diseases
- A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts (2020)
- Journal of Medical Virology
- Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study (2020)
- Lancet Infectious Diseases
- Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. (2020)
- Eurosurveillance
- Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials (2020) Shankar-Hari M, Estcourt L, Harvala H, Roberts D, Menon DK, United Kingdom SARS-CoV-2 Convalescent Plasma Evaluation (SCoPE) Consortium
- Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. (2020)
- Eurosurveillance
- Correction to: Recommendations for the nomenclature of enteroviruses and rhinoviruses (2020)
- Archives of Virology
- Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. (2020)
- Eurosurveillance
- Measles is Back - Considerations for laboratory diagnosis (2020)
- Journal of Clinical Virology
- Recommendations for the nomenclature of enteroviruses and rhinoviruses (2020)
- Archives of Virology
- SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus (2020)
- Wellcome Open Research